OK-432联合过继性免疫疗法对乳腺癌肝转移的治疗效果。
The therapeutic effect of OK-432-combined adoptive immunotherapy against liver metastases from breast cancer.
作者信息
Okino T, Kan N, Nakanishi M, Satoh K, Mise K, Teramura Y, Yamasaki S, Hori T, Kodama H, Ohgaki K
机构信息
First Department of Surgery, Kyoto University, School of Medicine, Japan.
出版信息
J Cancer Res Clin Oncol. 1990;116(2):197-202. doi: 10.1007/BF01612677.
We studied the therapeutic effect of OK-432 combined with adoptive immunotherapy in 19 cases of liver metastases from breast cancer. Of the 14 patients who received intraarterial OK-432 injection and transfer of cultured lymphocytes, 9 responded to this therapy, whereas no patients responded to intravenous administration. The minimum cell number for a therapeutic response was 8 x 10(8) cells. Metastatic lesions other than those in the liver regressed after therapy in 4 patients. The serum carcinoembryonic antigen level paralleled the therapeutic effect. There were no severe side-effects accompanying this therapy. These results indicate that intraarterial adoptive immunotherapy combined with OK-432 is effective as a new therapeutic approach against liver metastases from breast cancer.
我们研究了OK-432联合过继性免疫疗法对19例乳腺癌肝转移患者的治疗效果。在14例接受动脉内注射OK-432及培养淋巴细胞输注的患者中，9例对该治疗有反应，而静脉给药组无患者有反应。产生治疗反应的最小细胞数为8×10⁸个细胞。4例患者除肝脏转移灶外的其他转移病灶在治疗后消退。血清癌胚抗原水平与治疗效果平行。该治疗未伴随严重副作用。这些结果表明，动脉内过继性免疫疗法联合OK-432作为一种针对乳腺癌肝转移的新治疗方法是有效的。
Zotero 插件